Using epigenetic compounds to help repair dental bone loss
Official title: Epigenetic Compounds Stimulating Dental Bone Repair
Funded at Cayman Chemical Company, INC. · NIH-11067062 · Data updated 2026-11-12
This study is looking at a new way to help older adults with periodontitis, a gum disease that can cause bone loss around teeth, by using special treatments that might help grow new bone and repair the damage.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cayman Chemical Company, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | April 8, 2025 |
| Project end | April 7, 2026 |
| Funding year | 2025 |
| Award (this year) | $306,868 |
| NIH project number | 1R43DE034602-01 |
| Project ID | NIH-11067062 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing alveolar bone loss due to periodontitis, particularly older adults.
✕Less likely to help
Patients who do not have periodontitis or significant alveolar bone loss may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for patients suffering from periodontitis, a condition that leads to the loss of alveolar bone around teeth. By targeting specific epigenetic enzymes, the study aims to stimulate the growth of bone-forming cells, potentially reversing the damage caused by chronic inflammation. The approach involves using small molecules that can be incorporated into various delivery methods, making it a cost-effective and versatile option for patients. The research is particularly relevant for older adults who are more susceptible to bone loss in the mouth.
Why it matters
Potential benefit: If successful, this research could provide a novel and affordable treatment option for patients with dental bone loss, improving their oral health and quality of life.
How similar studies have gone: Previous studies have shown promising results with similar approaches targeting epigenetic mechanisms to promote bone regeneration.
Where this research is happening
-
Cayman Chemical Company, INC.
Ann Arbor, United States Active
Researchers
- Principal investigator: Kennedy, Paul Douglas — Cayman Chemical Company, INC.
- Study coordinator: Kennedy, Paul Douglas
Related research
Other NIH-funded projects on the same topics.
-
New small molecule to enhance dental implant integration with bone
This study is testing a new medicine that could help people with weak bones, like those with osteoporosis, get dental implants that fit better and last longer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.